Benitec Biopharma Price to Sales Ratio 2014-2023 | BNTC
Historical PS ratio values for Benitec Biopharma (BNTC) over the last 10 years. The current P/S ratio for Benitec Biopharma as of May 31, 2023 is .
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Benitec Biopharma P/S Ratio Historical Data |
| Date |
Stock Price |
TTM Sales per Share |
Price to Sales Ratio |
| 2023-05-31 |
0.24 |
|
98.90 |
| 2023-03-31 |
0.21 |
$0.00 |
0.00 |
| 2022-12-31 |
0.17 |
$0.01 |
0.00 |
| 2022-09-30 |
0.37 |
$0.01 |
0.00 |
| 2022-06-30 |
1.16 |
$0.01 |
0.00 |
| 2022-03-31 |
2.34 |
$0.01 |
0.00 |
| 2021-12-31 |
2.62 |
$0.00 |
0.00 |
| 2021-09-30 |
3.57 |
$0.00 |
0.00 |
| 2021-06-30 |
4.25 |
$0.05 |
84.08 |
| 2021-03-31 |
5.17 |
$-7.01 |
0.00 |
| 2020-12-31 |
3.00 |
$1.98 |
1.51 |
| 2020-09-30 |
6.28 |
$1.98 |
3.17 |
| 2020-06-30 |
7.91 |
$1.93 |
4.09 |
| 2016-09-30 |
14.00 |
$8.99 |
1.56 |
| 2016-06-30 |
12.68 |
$5.19 |
2.45 |
| 2016-03-31 |
17.10 |
$5.19 |
3.30 |
| 2015-12-31 |
40.20 |
$5.22 |
7.70 |
| 2020-03-31 |
3.93 |
$6.41 |
0.61 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.006B |
$0.000B |
|
Benitec Biopharma Limited is a biotechnology company which developed a patented gene silencing technology delivered by gene therapy called DNA directed RNA interference. The company is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including hepatitis C and B, drug resistant lung cancer and wet age-related macular degeneration. Benitec Biopharma Limited is based in Sydney, Australia.
|
